Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$12.29
+19.9%
$15.40
$10.00
$29.60
$46.44M0.9838,180 shs169,313 shs
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$5.08
+0.2%
$10.15
$7.19
$14.68
$69.04M0.392,386 shs1,377 shs
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
$0.07
-12.5%
$0.09
$0.06
$0.17
$7.83M0.0734,446 shs8,088 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
+19.90%-14.91%-17.67%-8.96%-40.34%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-3.42%+0.99%-2.31%-16.72%+1.60%
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
-12.50%0.00%-29.29%-41.62%-3.98%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.8311 of 5 stars
3.53.00.04.61.60.80.6
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
3.7543 of 5 stars
3.34.00.04.60.62.50.0
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.00
Buy$93.33659.43% Upside
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
2.50
Moderate Buy$7.5047.64% Upside
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/AN/AN/AN/A

Current Analyst Ratings

Latest CDTX, ANCR, CSBR, and PURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
4/8/2024
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00
3/13/2024
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$63.91M17.43N/AN/A($0.04) per share-307.25
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$53.87M1.28N/AN/A$0.34 per share14.94
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
$1.87M4.19N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$29.80M-$0.24N/A19.51N/A-55.49%-264.84%-48.12%5/9/2024 (Estimated)
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$5.34M-$0.72N/AN/A-19.76%-850.72%-32.62%7/22/2024 (Estimated)
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
-$3.96M-$0.06N/AN/A-194.80%-717.03%-326.30%6/12/2024 (Estimated)

Latest CDTX, ANCR, CSBR, and PURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q2 2024
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/A-$0.01-$0.01-$0.01N/A$0.33 million
3/12/2024Q3 2024
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A-$0.19-$0.19-$0.19N/A$12.02 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
1.62
1.55
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
0.60
0.60
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
3.75
1.72
1.59

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
7.43%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
45.69%
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
41.76%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
7390.62 million83.89 millionOptionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
14313.59 million7.38 millionOptionable
PURE Bioscience, Inc. stock logo
PURE
PURE Bioscience
11111.86 million65.15 millionNot Optionable

CDTX, ANCR, CSBR, and PURE Headlines

SourceHeadline
East Butler, Shelby-Rising City track in action at Twin RiverEast Butler, Shelby-Rising City track in action at Twin River
columbustelegram.com - April 23 at 8:08 AM
Final Fantasy XVI The Rising Tide Review (PS5)Final Fantasy XVI The Rising Tide Review (PS5)
heypoorplayer.com - April 23 at 8:08 AM
Catalase Market Expansion: A Close Look at the US$ 516.6 Million Forecast by 2032 | Future Market Insights Inc.Catalase Market Expansion: A Close Look at the US$ 516.6 Million Forecast by 2032 | Future Market Insights Inc.
fmiblog.com - April 23 at 8:08 AM
PURE Bioscience, Inc. (PURE)PURE Bioscience, Inc. (PURE)
finance.yahoo.com - April 15 at 9:22 PM
Seragon Biosciencess RESTORIN Revolutionizes the Anti-Aging MarketSeragon Biosciences's RESTORIN Revolutionizes the Anti-Aging Market
ibtimes.com - April 15 at 4:22 PM
4JO: Burg Presents USAC Sprint Midwest Opener on Saturday4JO: Burg Presents USAC Sprint Midwest Opener on Saturday
speedwaydigest.com - April 13 at 8:30 PM
Pro-Palestine group at Harvard organizes student referendum on Israel divestmentPro-Palestine group at Harvard organizes student referendum on Israel divestment
forward.com - April 12 at 8:29 AM
Harvard Student Government Approves PSC Petition for Referendum on Israel DivestmentHarvard Student Government Approves PSC Petition for Referendum on Israel Divestment
thecrimson.com - April 11 at 10:20 AM
Top Iconic Brands to watch in 2024Top Iconic Brands to watch in 2024
timesofindia.indiatimes.com - April 1 at 12:36 PM
New school-wide dress code inspires unprecedented backlashNew school-wide dress code inspires unprecedented backlash
msuexponent.com - March 28 at 8:09 PM
UVA Law Professor Discusses Judicial Deference at Harvard Law School’s Annual Scalia LectureUVA Law Professor Discusses Judicial Deference at Harvard Law School’s Annual Scalia Lecture
thecrimson.com - March 28 at 1:25 PM
Scientists say theyre closer to reviving Mammoths. What could go wrong?Scientists say they're closer to reviving Mammoths. What could go wrong?
msn.com - March 28 at 1:25 PM
Sam Altmans mission to increase human lifespan with a $180 million shipping container experiment at Retro BiosciencesSam Altman's mission to increase human lifespan with a $180 million shipping container experiment at Retro Biosciences
msn.com - March 23 at 10:16 AM
PURE Bioscience Reports Fiscal Second Quarter 2024 Financial ResultsPURE Bioscience Reports Fiscal Second Quarter 2024 Financial Results
businesswire.com - March 18 at 4:05 PM
Research: Red clover can act to deliver improved silage qualityResearch: Red clover can act to deliver improved silage quality
agriland.ie - March 16 at 10:49 PM
As European dynamism gathers momentum, Elaia and partners double down with new deep tech fundAs European dynamism gathers momentum, Elaia and partners double down with new deep tech fund
yahoo.com - March 14 at 1:57 AM
Sophie Bai Creates Scientific Breakthroughs for Her Skincare Brand, PaviseSophie Bai Creates Scientific Breakthroughs for Her Skincare Brand, Pavise
wmagazine.com - March 13 at 8:06 PM
Kuros Biosciences AG: Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023Kuros Biosciences AG: Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023
finanznachrichten.de - March 13 at 10:05 AM
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
markets.businessinsider.com - March 13 at 10:05 AM
Resurrecting the mammoth: Elephant breakthrough gets us a step closerResurrecting the mammoth: Elephant breakthrough gets us a step closer
newatlas.com - March 13 at 10:05 AM
Imo Assembly Threatens Closure Of Pure Water FactoriesImo Assembly Threatens Closure Of Pure Water Factories
leadership.ng - March 12 at 1:50 PM
Global Catalase Market Set to Reach US$ 516.6 Million by 2032 with a 2.9% CAGR SurgeGlobal Catalase Market Set to Reach US$ 516.6 Million by 2032 with a 2.9% CAGR Surge
fmiblog.com - March 12 at 1:50 PM
Activists petition to remove methylene chloride from common decaf coffee production method amid carcinogen concernsActivists petition to remove methylene chloride from common decaf coffee production method amid carcinogen concerns
foodnavigator-usa.com - March 11 at 8:36 PM
How are peptide barcodes used for NGS?How are peptide barcodes used for NGS?
news-medical.net - March 11 at 3:35 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cidara Therapeutics logo

Cidara Therapeutics

NASDAQ:CDTX
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Champions Oncology logo

Champions Oncology

NASDAQ:CSBR
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
PURE Bioscience logo

PURE Bioscience

OTCMKTS:PURE
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.